1-6 of 6
Christopher A. Maxwell
Close
Sort by
Journal Articles

Targeting aurora kinases as therapy in multiple myeloma

Yijiang Shi, Tony Reiman, Weiqun Li, Christopher A. Maxwell, Subrata Sen, Linda Pilarski, Tracy R. Daniels, Manuel L. Penichet, Rick Feldman, Alan Lichtenstein
Journal: Blood
Blood (2007) 109 (9): 3915–3921.
https://doi.org/10.1182/blood-2006-07-037671
Published: 2007
Journal Articles

Aurora Kinases as Therapeutic Targets in Multiple Myeloma.

Tony Reiman, Robert P. Evans, Claudia Naber, Tara Steffler, Jonathan J. Keats, Troy Perry, Christopher A. Maxwell, Heidi Chau, Andrew R. Belch, Linda M. Pilarski
Journal: Blood
Blood (2006) 108 (11): 847.
https://doi.org/10.1182/blood.V108.11.847.847
Published: 2006
Journal Articles

Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients

Jonathan J. Keats, Christopher A. Maxwell, Brian J. Taylor, Michael J. Hendzel, Marta Chesi, P. Leif Bergsagel, Loree M. Larratt, Michael J. Mant, Tony Reiman, Andrew R. Belch, Linda M. Pilarski
Journal: Blood
Blood (2005) 105 (10): 4060–4069.
https://doi.org/10.1182/blood-2004-09-3704
Published: 2005
Journal Articles

Altered Kinetics and Localization of MMSET Variants Suggests That RE-IIBP Overexpression Is a Unifying Event in t(4;14)(p16;q32) Multiple Myeloma.

Jonathan J. Keats, Christopher A. Maxwell, PhD, Tony Reiman, MD, Brian J. Taylor, PhD, Michael J. Mant, MD, Andrew J. Belch, MD, Linda M. Pilarski, PhD
Journal: Blood
Blood (2004) 104 (11): 75.
https://doi.org/10.1182/blood.V104.11.75.75
Published: 2004
Journal Articles

RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma

Clinical Trials & Observations
Christopher A. Maxwell, Erik Rasmussen, Fenghuang Zhan, Jonathan J. Keats, Sophia Adamia, Erin Strachan, Mary Crainie, Ronald Walker, Andrew R. Belch, Linda M. Pilarski, Bart Barlogie, John Shaughnessy, Jr, Tony Reiman
Journal: Blood
Blood (2004) 104 (4): 1151–1158.
https://doi.org/10.1182/blood-2003-11-4079
Published: 2004
Journal Articles

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression

Clinical Trials & Observations
Jonathan J. Keats, Tony Reiman, Christopher A. Maxwell, Brian J. Taylor, Loree M. Larratt, Michael J. Mant, Andrew R. Belch, Linda M. Pilarski
Journal: Blood
Blood (2003) 101 (4): 1520–1529.
https://doi.org/10.1182/blood-2002-06-1675
Published: 2003